INTRODUCTION
============

Allergic rhinitis (AR) is a common disease worldwide, and its prevalence has increased in industrialized countries over the last few decades^[@ref1]-[@ref5])^. AR is generally defined as an immunoglobulin E (IgE)-mediated inflammatory response of the nasal mucous membrane. This reaction is induced by exposure to specific allergens such as pollen, dust mites, molds, and pets. Pollen is suspected as a major cause of seasonal AR, whereas other allergens are associated with perennial AR. The major allergens for seasonal AR in Japan are pollen from Japanese cedar (*Cryptomeria japonica*; sugi) and Japanese cypress (*Chamaecyparis obtusa*; hinoki)^[@ref6])^. The dispersion of Japanese cedar pollen generally peaks between February and April^[@ref7])^, and Japanese cypress pollen is dispersed from April to May. Moreover, 70% of cedar pollinosis patients also experience seasonal AR as a result of cypress pollinosis; thus, the allergic symptoms caused by these types of pollinosis can continue for up to 4 months^[@ref8])^. Therefore, pollinosis is considered a common health issue in Japan^[@ref9]-[@ref11])^.

From an economic standpoint, the medical expenses associated with AR management are considerable^[@ref12])^. From the patient's perspective, AR adversely influences quality of life because of widespread symptoms such as sneezing, watery rhinorrhea, nasal congestion, and/or itchy nose. Previous studies reported that these symptoms affect daytime activity, work productivity, and sleep quality in patients^[@ref8],[@ref13],[@ref14])^. In children, seasonal AR impacts on learning performance and impairs behavior and attention^[@ref15],[@ref16])^.

To better understand the genetic factors underlying AR, genome-wide association studies (GWAS) have recently been conducted. A genome-wide meta-analysis by Ramasamy et al. identified three single nucleotide polymorphisms (SNPs) with genome-wide significance and 12 loci with suggestive associations of AR and grass sensitization^[@ref17])^. Hinds et al. found 16 shared loci associated with self-reported cat, dust mite, and pollen allergy^[@ref18])^. Further, Bønnelykke et al. reported that 10 loci are significantly associated with allergic sensitization in Caucasian individuals^[@ref19])^. Combining the findings from previous GWAS together, only four loci (*toll-like receptor (TLR)6-TLR1*, *HLA-DQA2-HLA-DQA1*, *interleukin (IL)2-ADA1*, and *LRRC32-C11orf30*) of all 47 SNPs overlap. Although considerable work has been performed to identify genetic variants associated with allergic traits such as AR, prior studies have focused almost exclusively on subjects of European descent^[@ref17]-[@ref22])^. However, recent work suggests that GWAS in non-European populations are needed to elucidate ethnically different variants^[@ref23])^. In Japan, although there have been some candidate gene studies on pollinosis^[@ref24]-[@ref29])^, no GWAS has been conducted. The aim of our study was to conduct a genome-wide agnostic screening for genetic loci associated with self-reported pollinosis, a major cause of seasonal AR, in a Japanese genome cohort study. Furthermore, to augment our single-SNP screen, we also utilized gene- and pathway-based analyses to expand our knowledge on the molecular factors underlying pollinosis.

MATERIALS AND METHODS
=====================

The present study was nested within the broader Japan Multi-Institutional Collaborative Cohort (J-MICC) Study, a large-scale cohort study performed in Japan. The aim of the J-MICC Study is to examine and detect gene--environmental interactions associated with lifestyle-related diseases, primarily cancer. This cohort study was launched in 2005, and the recruitment of 100,000 participants was completed in March 2014. Participants in the J-MICC Study are individuals aged 35 to 69 years who enrolled by responding to study announcements in 14 different areas throughout Japan. The J-MICC Study has been well-described previously^[@ref30])^ and on its website (URL: <http://www.jmicc.com/>). In our current study, we performed a two-stage GWAS using information from two independent sites. The first stage was for screening (discovery phase) and the second stage for confirming the findings from the first stage (replication phase). In both phases, all research procedures complied with the Ethical Guidelines for Human Genome and Genetic Sequencing Research in Japan.

Discovery phase (Daiko Study)
-----------------------------

The discovery phase analysis was carried out using data from the participants of the Daiko Study, one of the study sites of the J-MICC Study. A total of 766 individuals (231 men and 535 women) with information on pollinosis history were selected for this analysis. At this site, we inquired about three different types of pollinosis (the presence of any pollinosis, Japanese cedar pollinosis, and Japanese cypress pollinosis) using a self-administered questionnaire. Written informed consent was obtained from all participants. The protocol of this study was approved by the Ethics Review Committee of the Nagoya University Graduate School of Medicine (No. 2015-0274).

Replication phase (Shizuoka--Sakuragaoka Study)
-----------------------------------------------

We used data from the baseline survey of the Shizuoka--Sakuragaoka Study, another site of the J-MICC Study, to validate the findings from the discovery phase. In this phase, 581 participants (360 men and 221 women) were included. Participants at this site were asked only whether they had a pollen allergy or not. We obtained written informed consent from all participants. The protocol of this study was approved by the Ethics Committee of the University of Shizuoka (No. 22-39).

Genotyping and quality control
------------------------------

DNA samples were automatically extracted from all buffy-coat fractions using the BioRobot M48 Workstation (QIAGEN Group, Tokyo, Japan). For both the discovery and replication phases, 964,193 SNPs were genotyped using the Illumina HumanOmniExpressExome ver1.2 platform (Illumina, San Diego, CA) at the RIKEN Center for Integrative Medical Sciences (Yokohama, Japan). At the quality control (QC) phase, we excluded SNPs matching any one of the following five criteria: (1) call rate \< 98%, (2) Hardy--Weinberg equilibrium *P* \< 1 × 10^−6^, (3) minor allele frequency \< 0.01, (4) insertion and deletion, and (5) non-autosomal SNP (X, Y, mitochondrial chromosome) and linkage disequilibrium (LD) pruning. After the QC for SNPs, participants who had a proportion of identity by descent \> 0.1875 and outliers in a principal component analysis were excluded. Following QC, a total of 570,398 SNPs were finally available for the analysis of 731 and 560 individuals in the discovery and replication phases, respectively.

Single-SNP analysis
-------------------

All statistical analyses were performed using software R ver3.3.1 and PLINK ver1.07. Principal components (PCs) were calculated by EIGENSOFT ver6.1.4 to remove the influence of population stratification^[@ref31])^. We carried out a logistic regression to screen the associations between pollinosis and each individual SNP. SNPs were coded under an additive genetic model, and a logistic regression analysis with adjustment for age, sex, and the top five PCs was conducted. *P*-values \< 5 × 10^−8^ and \< 1 × 10^−4^ were considered to signify genome-wide significance and suggestive significance, respectively. A combined *P*-value in both phases was calculated using Fisher's method^[@ref32])^.

Gene- and pathway-based analyses
--------------------------------

To augment our single-SNP analysis, we then performed gene- and pathway-based analyses to identify particular genes and pathways associated with pollinosis. We used the sequence kernel association test (SKAT)^[@ref33],[@ref34])^, which allows us to test for associations between a group of genetic variants in a gene or pathway and outcomes, with adjustment for covariates. Briefly, the approach works by comparing pairwise similarity in phenotypes to pairwise similarity in genotypes as measured through a kernel function. Different kernel functions capture different underlying models. Gene-based SNP sets for each study were created by matching SNPs to gene locations, which were determined using the UCSC Genome Browser (GRCh37) database. We analyzed a total of 24,756 genes (447,224 SNPs) in the discovery phase and 24,717 genes (427,203 SNPs) in the replication phase. Pathway-based SNP sets were subsequently generated by aggregating the SNPs within genes comprising pathways. Gene--pathway membership was confirmed using the Kyoto Encyclopedia of Genes and Genomes Pathway Database. In the pathway-based approach, we selected 10 biologically plausible pathways associated with pollinosis: (1) asthma, (2) B cell receptor signaling, (3) cytokine receptors, (4) Fc gamma R-mediated phagocytosis, (5) nuclear factor-kappa B signaling, (6) natural killer cell-mediated cytotoxicity, (7) nucleotide-binding oligomerization domain-like receptor (NLR) signaling, (8) T cell receptor signaling, (9) TLR signaling, and (10) tumor necrosis factor (TNF) signaling. *P*-values in the discovery phase were corrected for the false discovery rate (FDR) using the Benjamini--Hochberg method^[@ref35])^. The significance threshold after FDR correction was set at *P* \< 0.25 in the present study. The genes and pathways passing the threshold in the discovery phase were analyzed in the replication phase. All *P*-values in the replication phase were reported.

RESULTS
=======

Single-SNP analysis
-------------------

The demographic data of the participants in the discovery and replication phases are summarized in [Table 1](#table1){ref-type="table"}. We identified no SNPs meeting the genome-wide significance level (*P* \< 5 × 10^−8^) when comparing those with each of the allergen-specific types of pollinosis (cedar and cypress pollinosis) and those without. However, 58 SNPs showed associations with both types of pollinosis at the suggestive significance level (*P* \< 1 × 10^−4^). The GWAS for cedar and cypress pollinosis identified 42 and 54 SNPs that reached the suggestive threshold, respectively. Consequently, 123 unique SNPs passed into the replication phase in the 560 unrelated samples. Our replication study identified six significant SNPs out of these 123 loci. However, when comparing the results of the discovery phase with those of the replication phase, two of the six significant SNPs were inconsistent in their direction of effects across the phases ([Table 2](#table2){ref-type="table"}). The four remaining SNPs at rs11975199 between *LOC100631260* and *MARK2P7* (OR = 0.76, *P* = 0.024), rs11979076 between *LOC100631260* and *MARK2P7* (OR = 0.75, *P* = 0.021), rs11979422 between *LOC100631260* and *MARK2P7* (OR = 0.76, *P* = 0.024), and rs12669708 in *MARK2P7* (OR = 0.77, *P* = 0.034) showed consistent effects in the two phases. When we combined the *P*-values in the discovery and replication phases, no SNPs reached genome-wide significance levels.

###### 

The characteristics of the participants in the discovery and replication phases

                     Discovery phase                 Replication phase      
  ------------------ ----------------- ------------- ------------------- -- -------------
  N                  731               649           554                    560
  Age (Mean, SD)     53.1 (10.6)       53.2 (10.5)   53.3 (10.7)            50.2 (9.4)
  Sex (Male)         222 (30.4%)       195 (30.0%)   164 (29.6%)            344 (61.4%)
  Pollinosis (Yes)   311 (42.5%)       229 (35.3%)   134 (24.2%)            277 (49.5%)

###### 

Summary of results in the single-SNP association test

  -------------------------------------------------------------------------------------------------------------------
  SNP          CHR   Major allele   MAF    Discovery phase              Replication phase                     
  ------------ ----- -------------- ------ ----------------- ---------- ------------------- -- -------------- -------
  rs11617981   13    *C*            0.45   1.60\             9.83E-05   Cedar                  0.77\          0.036
                                           (1.26--2.02)                                        (0.61--0.98)   

  rs540607     19    *T*            0.21   1.98\             5.55E-05   Cypress                0.73\          0.045
                                           (1.42--2.76)                                        (0.54--0.99)   

  rs11975199   7     *A*            0.43   0.54\             7.30E-05   Cypress                0.76\          0.024
                                           (0.40--0.73)                                        (0.59--0.96)   

  rs11979076   7     *T*            0.43   0.54\             7.30E-05   Cypress                0.75\          0.021
                                           (0.40--0.73)                                        (0.59--0.96)   

  rs11979422   7     *A*            0.43   0.54\             7.30E-05   Cypress                0.76\          0.024
                                           (0.40--0.73)                                        (0.59--0.96)   

  rs12669708   7     *G*            0.44   0.55\             8.41E-05   Cypress                0.77\          0.034
                                           (0.40--0.74)                                        (0.60--0.98)   
  -------------------------------------------------------------------------------------------------------------------

CHR, chromosome; MAF, minor allele frequency; OR, odds ratio; 95% CI, 95% confidence interval.

Gene-based analysis
-------------------

In the discovery phase, the gene-based analysis identified no significant or suggestive genes for the risk of all pollinosis and cedar pollinosis. For cypress pollinosis, we identified two suggestive genes that passed the criteria into the replication phase: *PHF13* (chromosome 1, *Q*~linear~ = 0.244) and *KLHL21* (chromosome 1, *Q*~linear~ = 0.244) ([Table 3](#table3){ref-type="table"}). In the replication phase, however, neither *PHF13* nor *KLHL21* was significantly associated with pollinosis (*P*~linear~ = 0.489 and 0.459, respectively). Integrated analysis also showed no significant genes.

###### 

The results of the gene-based analysis in the discovery and replication phases (in linear kernel function)

  Gene name   Discovery phase^a^           Replication phase^b^      
  ----------- -------------------- ------- ---------------------- -- -------
  *PHF13*     0.945                0.814   0.244                     0.489
  *KLHL21*    0.945                0.814   0.244                     0.459

^a^*Q*-values (Benjamini-Hochberg method-corrected *P*-values) are shown.

^b^*P*-values were not corrected in the replication phase.

Pathway-based analysis
----------------------

In the discovery phase, pathway-based analysis identified one significant and one suggestive pathway related to pollinosis ([Table 4](#table4){ref-type="table"}). The NLR signaling pathway showed a significant relationship with cypress pollinosis when we applied linear and identity-by-state (IBS) kernel function (*Q*~linear~ = 0.025 and *Q*~IBS~ = 0.045, respectively). The TNF signaling pathway reached a suggestive significance level of association with cedar pollinosis (*Q* = 0.231). The SKAT results in the replication phase are shown in [Table 5](#table5){ref-type="table"}. The NLR and TNF signaling pathways reached a suggestive significance level (*P* = 0.094 and 0.095 in linear kernel function, respectively). Thus, the NLR and TNF signaling pathways seem to be candidate pathways for association with pollinosis.

###### 

The results of the pathway-based analysis in the discovery phase (*Q*-value)

  ---------------------------------------------------------------------------------------------------------------------------------------
  Pathway                                     All pollinosis             Cedar               Cypress                      
  ------------------------------------------- ---------------- --------- ------- ----------- --------- -- --------------- ---------------
  Asthma                                      0.861/\          0.808/\           0.888/\     0.873/\      0.642/\         0.582/\
                                              0.741            0.808             0.549       0.487        0.859           0.885

  B cell receptor signaling                   0.861/\          0.808/\           0.888/\     0.873/\      0.730/\         0.582/\
                                              0.741            0.808             0.904       0.905        0.877           0.885

  Cytokine receptors                          0.888/\          0.912/\           0.888/\     0.873/\      0.783/\         0.582/\
                                              0.808            0.822             0.549       0.487        0.859           0.885

  Fc gamma R-mediated phagocytosis            0.861/\          0.808/\           0.888/\     0.873/\      0.959/\         0.915/\
                                              0.808            0.822             0.904       0.905        0.877           0.885

  Nuclear factor (NF)-kappa B signaling       0.861/\          0.808/\           0.888/\     0.873/\      0.642/\         0.582/\
                                              0.741            0.808             0.549       0.529        0.877           0.885

  Natural killer cell-mediated cytotoxicity   0.861/\          0.808/\           0.801/\     0.873/\      0.619/\         0.582/\
                                              0.808            0.838             0.904       0.905        0.859           0.885

  NOD-like receptor signaling                 0.861/\          0.808/\           0.888/\     0.873/\      0.025^\*\*^/\   0.045^\*\*^/\
                                              0.808            0.822             0.549       0.487        0.859           0.885

  T cell receptor signaling                   0.861/\          0.808/\           0.888/\     0.873/\      0.866/\         0.760/\
                                              0.741            0.808             0.498       0.487        0.859           0.885

  Toll-like receptor signaling                0.888/\          0.916/\           0.888/\     0.873/\      0.647/\         0.582/\
                                              0.741            0.822             0.549       0.487        0.859           0.885

  Tumor necrosis factor (TNF) signaling       0.861/\          0.808/\           0.888/\     0.873/\      0.959/\         0.930/\
                                              0.741            0.808             0.231^\*^   0.408        0.877           0.885
  ---------------------------------------------------------------------------------------------------------------------------------------

Linear, linear kernel; W.linear, weighted linear kernel; IBS, IBS kernel; W.IBS, weighted IBS kernel. \*\*: *Q*-value \< 0.1, \*: *Q*-value \< 0.25.

###### 

The results of the pathway-based analysis in the replication phase (*P*-value)

                                          Linear      W.linear   IBS     W.IBS
  --------------------------------------- ----------- ---------- ------- -------
  NOD-like receptor (NLR) signaling       0.094^\*^   0.427      0.223   0.269
  Tumor necrosis factor (TNF) signaling   0.095^\*^   0.987      0.171   0.961

Linear: linear kernel; W.linear: weighted linear kernel; IBS: IBS kernel; W.IBS: weighted IBS kernel. \*: *P*-value \< 0.1.

Retrace (pathway--gene--SNP) analysis
-------------------------------------

We again performed gene-based tests by focusing on genes in the TNF and NLR signaling pathways that reached suggestive significance levels in the pathway analysis. No significant genes were observed in the TNF signaling pathway, although six genes in the NLR signaling pathway passed the threshold of *Q*-value \< 0.25 in the discovery phase ([Table 6](#table6){ref-type="table"}). Of these genes, only the *IL-1B* gene was found to be associated with pollinosis in the replication phase (*P*~linear~ = 0.022 and *P*~IBS~ = 0.027) ([Table 7](#table7){ref-type="table"}). Thus, we traced back the results of the single-SNP test to find unique loci associated with pollinosis. As shown in [Table 8](#table8){ref-type="table"} and [9](#table9){ref-type="table"}, two SNPs (rs1143633 and rs3917368) in *IL-1B* were significantly associated with pollinosis in both phases without correction for multiple comparison.

###### 

The results of the gene-based analysis in the NOD-like receptor (NLR) signaling pathway in the discovery phase (*Q*-value)

  -------------------------------------------------------------------------------------------------------
            All pollinosis             Cedar               Cypress                          
  --------- ---------------- --------- ------- ----------- ------------- -- --------------- -------------
  *TAB2*    0.464/\          0.635/\           0.447/\     0.611/\          0.065^\*\*^/\   0.130^\*^/\
            0.513            0.557             0.388       0.524            0.070^\*\*^     0.139^\*^

  *MAPK9*   0.715/\          0.635/\           0.447/\     0.113^\*^/\      0.533/\         0.626/\
            0.681            0.557             0.428       0.158^\*^        0.541           0.669

  *CARD9*   0.464/\          0.661/\           0.441/\     0.611/\          0.056^\*\*^/\   0.626/\
            0.513            0.557             0.305       0.524            0.070^\*\*^     0.698

  *CARD6*   0.715/\          0.635/\           0.511/\     0.203^\*^/\      0.540/\         0.626/\
            0.642            0.557             0.388       0.267            0.507           0.669

  *CARD8*   0.949/\          0.950/\           0.867/\     0.878/\          0.204^\*^/\     0.626/\
            0.910            0.838             0.869       0.557            0.128^\*^       0.669

  *IL1B*    0.464/\          0.961/\           0.441/\     0.878/\          0.540/\         0.874/\
            0.513            1.000             0.198^\*^   0.801            0.507           0.892
  -------------------------------------------------------------------------------------------------------

Linear, linear kernel; W.linear, weighted linear kernel; IBS, IBS kernel; W.IBS, weighted IBS kernel. \*\*: *Q*-value \< 0.1, \*: *Q*-value \< 0.25.

###### 

The results of the gene-based analysis in the NOD-like receptor (NLR) signaling pathway in the replication phase (*P*-value)

            Linear      W.linear   IBS         W.IBS
  --------- ----------- ---------- ----------- -------
  *TAB2*    0.503       0.503      0.496       0.496
  *MAPK9*   0.525       0.339      0.665       0.206
  *CARD9*   0.445       0.18       0.602       0.228
  *CARD6*   0.586       0.196      0.736       0.241
  *CARD8*   0.284       0.326      0.391       0.417
  *IL1B*    0.022^\*^   0.179      0.027^\*^   0.155

Linear: linear kernel; W.linear: weighted linear kernel; IBS: IBS kernel; W.IBS: weighted IBS kernel. \*: *P*-value \< 0.05.

###### 

Results of the single-SNP association test in the *IL1B* region in the discovery phase (no correction for multiple comparison)

  ----------------------------------------------------------------------------------------------------------------
  SNP\               All pollinosis               Cedar                  Cypress                       
  \[Major allele\]                                                                                     
  ------------------ ---------------- ----------- ------- -------------- ----------- -- -------------- -----------
  exm2265188 \[G\]   1.23\            0.062               1.22\          0.102          1.24\          0.144
                     (0.99--1.52)                         (0.96--1.55)                  (0.93--1.66)   

  rs10169916 \[T\]   1.24\            0.053               1.22\          0.101          1.24\          0.144
                     (0.99--1.53)                         (0.96--1.55)                  (0.93--1.66)   

  rs1071676 \[G\]    0.97\            0.912               1.22\          0.465          1.13\          0.716
                     (0.58--1.62)                         (0.72--2.06)                  (0.60--2.12)   

  rs1143633 \[C\]    1.29\            0.018^\*^           1.35\          0.012^\*^      1.32\          0.056
                     (1.04--1.60)                         (1.07--1.72)                  (0.99--1.75)   

  rs1143634 \[A\]    0.97\            0.912               1.22\          0.465          1.13\          0.716
                     (0.58--1.62)                         (0.72--2.06)                  (0.60--2.12)   

  rs12621220 \[T\]   1.17\            0.170               1.18\          0.195          1.07\          0.660
                     (0.93--1.48)                         (0.92--1.52)                  (0.78--1.48)   

  rs16944 \[A\]      1.24\            0.051               1.23\          0.089          1.26\          0.116
                     (0.99--1.53)                         (0.97--1.56)                  (0.94--1.69)   

  rs2853550 \[A\]    1.02\            0.892               0.94\          0.722          1.12\          0.574
                     (0.75--1.39)                         (0.66--1.33)                  (0.75--1.67)   

  rs3136558 \[G\]    0.86\            0.153               0.87\          0.241          0.88\          0.377
                     (0.69--1.06)                         (0.69--1.10)                  (0.67--1.17)   

  rs3917366 \[A\]    0.97\            0.912               1.22\          0.465          1.13\          0.716
                     (0.58--1.62)                         (0.72--2.06)                  (0.60--2.12)   

  rs3917368 \[C\]    1.26\            0.034^\*^           1.32\          0.020^\*^      1.33\          0.049^\*^
                     (1.02--1.55)                         (1.04--1.68)                  (1.00--1.76)   

  rs7596684 \[C\]    1.05\            0.806               1.13\          0.565          1.16\          0.561
                     (0.71--1.55)                         (0.74--1.72)                  (0.71--1.90)   
  ----------------------------------------------------------------------------------------------------------------

SNP: single nucleotide polymorphism; OR: odds ratio; 95% CI: 95% confidence interval.

\*: *P* \< 0.05.

###### 

Results of the single-SNP association test in the *IL1B* region in the replication phase (no correction for multiple comparison)

  SNP \[Major allele\]   All pollinosis      
  ---------------------- ------------------- -----------
  exm2265188 \[G\]       1.05 (0.82--1.35)   0.697
  rs10169916 \[T\]       1.04 (0.81--1.33)   0.762
  rs1071676 \[G\]        1.44 (0.82--2.51)   0.204
  rs1143633 \[C\]        1.34 (1.04--1.72)   0.023^\*^
  rs1143634 \[A\]        1.44 (0.82--2.51)   0.204
  rs12621220 \[T\]       1.04 (0.81--1.35)   0.739
  rs16944 \[A\]          1.06 (0.83--1.36)   0.641
  rs2853550 \[A\]        0.82 (0.55--1.25)   0.360
  rs3136558 \[G\]        1.20 (0.94--1.52)   0.145
  rs3917366 \[A\]        1.44 (0.82--2.51)   0.204
  rs3917368 \[C\]        1.35 (1.05--1.73)   0.018^\*^
  rs7596684 \[C\]        1.32 (0.87--2.02)   0.194

SNP, single nucleotide polymorphism; OR, odds ratio; 95% CI, 95% confidence interval. \*: *P* \< 0.05.

DISCUSSION
==========

We performed a GWAS with single-SNP as well as gene- and pathway-based approaches to investigate the genetic etiology of pollinosis, including cedar and cypress pollinosis in Japan. We identified two possible loci associated with self-reported pollinosis in two independent studies, that is, the discovery phase (311 cases and 420 controls) and the replication phase (277 cases and 283 controls).

The present GWAS has three distinctive features. First, we believe that this is the first GWAS on pollinosis in a Japanese population. Earlier studies utilized candidate gene or pathway approaches. As for Asian populations, to the best of our knowledge, the only GWAS on allergic traits was conducted in a Chinese population from Singapore^[@ref36],[@ref37])^. Second, our results focused specifically on cedar and cypress pollen, which are major allergens of seasonal AR in Japan. This enabled us to gain an insight into allergen-specific mechanisms and enhance the study power, even with small sample sizes. Third, we attempted to use powerful gene- and pathway-based approaches to augment the standard GWAS analysis. Although little has been reported on the genes and pathways associated with pollinosis, a recent review by Bønnelykke et al. suggested the importance of grouped analysis^[@ref23])^. In the present study, we used SKAT for the gene and pathway analysis and found some plausible variants after identifying suggestive genes and pathways.

Two SNPs (rs1143633 and rs3917368) in the *IL1B* region on chromosome 2q14 were potentially associated with pollinosis in both the discovery and replication phases. IL-1 is a well-known pro-inflammatory cytokine involved in host defense and autoimmune disease^[@ref38])^. Additionally, a previous *in vitro* study demonstrated that IL releases histamine from basophils and mast cells, which implies an association between IL and human allergy reaction^[@ref39])^. In fact, genetic variants in *IL-1B*, a subtype of IL, have been related to the severity of chronic inflammation and autoimmune diseases such as asthma and atopic dermatitis^[@ref40]-[@ref42])^. Regarding rs1143633, a previous study has suggested an association between rs1143634 in *IL1B*, a SNP located 77 kb upstream of rs11343633, with AR^[@ref43])^. Furthermore, rs1143634 is reportedly linked to increased IL1B secretion^[@ref44])^. Additionally, rs1143634 has strong LD with rs1143627, a variant that alters transcription efficacy of *IL1B*^[@ref45])^, although we could not confirm the LD between rs1143633 and rs1143627. Taken together, we can presume that rs1143634, a nearby SNP of rs1143633, could potentially change the amount of IL-1B secretion. Another inference is that the association between rs1143627 and rs1143634 may modify *IL-1B* transcription. Moreover, the results of a previous study on a Chinese population in Taiwan suggested an association between rs3917368 in *IL1B* and Graves' ophthalmopathy, the most common symptom of Graves' disease^[@ref46])^. In a study on hand osteoarthritis, Moxley et al. observed strong LD of rs3917368 with rs16944, a well-known SNP in *IL1B* that can alter *IL-1B* transcription^[@ref47])^. Indeed, we confirmed moderate LD of rs3917368 and rs16944 in both phases (*r*^2^ = 0.435 and 0.361, respectively). In consideration of these findings, because rs3917368 has strong LD with rs16944, the former may be associated with immune systems through regulation of *IL-1B* gene expression.

Our study has several limitations. First, the phenotype definition of pollinosis was based on self-reported history, not on a blood test (*e.g.* IgE level) or skin prick test, which are routinely used for clinical diagnosis. However, consistency of the results between questionnaire-based and diagnosis-based pollinosis was shown in a previous study of AR^[@ref24])^. Second, the sample sizes in both phases (731 and 560, respectively) were smaller than those in typical GWAS, which might have made it difficult to find significant associations of SNPs found in previous studies on pollinosis. Nevertheless, we believe that our approaches provide a useful scientific basis for future studies on the genetic etiology underlying pollinosis.

In conclusion, we identified two variants in *IL-1B* associated with pollinosis in a Japanese population. Our gene- and pathway-based analyses may shed light on the molecular mechanisms of pollinosis. Further studies are expected to identify functionally related variants and shared loci for several allergic phenotypes.
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